Swedish Orphan Biovitrum AB (publ) Total Liabilities
Swedish Orphan Biovitrum AB (publ) total liabilities. Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) has total liabilities worth Skr40.87 Billion SEK (≈ $4.40 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SOBI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Swedish Orphan Biovitrum AB (publ) (2002–2025)
Total liabilities of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025. This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Swedish Orphan Biovitrum AB (publ) to see how much of total assets are deployed in long-term investments.
Swedish Orphan Biovitrum AB (publ) Competitors by Total Liabilities
The table below lists competitors of Swedish Orphan Biovitrum AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Illumina Inc
NASDAQ:ILMN
|
USA | $3.56 Billion |
|
Bouygues SA
PA:EN
|
France | €48.50 Billion |
|
TECHTRONIC INDS ADR/5
F:TIB
|
Germany | €6.47 Billion |
|
General Mills Inc
NYSE:GIS
|
USA | $22.64 Billion |
|
SGS SA
SW:SGSN
|
Switzerland | CHF6.98 Billion |
|
INTERCONT HOTELS
F:IC1B
|
Germany | €7.58 Billion |
|
Broadridge Financial Solutions Inc
NYSE:BR
|
USA | $5.96 Billion |
|
BANCO BRANDESCO SP.ADR 1
F:BREA
|
Germany | €2.15 Trillion |
Liability Composition Analysis (2002–2025)
This chart breaks down Swedish Orphan Biovitrum AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Swedish Orphan Biovitrum AB (publ) (SOBI) total assets.
Liquidity & Leverage Metrics
Swedish Orphan Biovitrum AB (publ) Total Liabilities Ratios Explained
Swedish Orphan Biovitrum AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Swedish Orphan Biovitrum AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Swedish Orphan Biovitrum AB (publ) (2002–2025)
The table below shows the annual total liabilities of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr29.71 Billion ≈ $3.20 Billion |
-15.47% |
| 2024-12-31 | Skr35.15 Billion ≈ $3.78 Billion |
-12.48% |
| 2023-12-31 | Skr40.16 Billion ≈ $4.32 Billion |
+54.63% |
| 2022-12-31 | Skr25.97 Billion ≈ $2.79 Billion |
+2.02% |
| 2021-12-31 | Skr25.46 Billion ≈ $2.74 Billion |
-9.33% |
| 2020-12-31 | Skr28.08 Billion ≈ $3.02 Billion |
-2.27% |
| 2019-12-31 | Skr28.73 Billion ≈ $3.09 Billion |
+252.79% |
| 2018-12-31 | Skr8.14 Billion ≈ $876.32 Million |
+93.77% |
| 2017-12-31 | Skr4.20 Billion ≈ $452.24 Million |
-9.04% |
| 2016-12-31 | Skr4.62 Billion ≈ $497.17 Million |
+27.57% |
| 2015-12-31 | Skr3.62 Billion ≈ $389.72 Million |
+95.98% |
| 2014-12-31 | Skr1.85 Billion ≈ $198.86 Million |
+5.59% |
| 2013-12-31 | Skr1.75 Billion ≈ $188.34 Million |
+18.21% |
| 2012-12-31 | Skr1.48 Billion ≈ $159.32 Million |
-14.73% |
| 2011-12-31 | Skr1.74 Billion ≈ $186.83 Million |
-36.34% |
| 2010-12-31 | Skr2.73 Billion ≈ $293.49 Million |
+87.73% |
| 2009-12-31 | Skr1.45 Billion ≈ $156.34 Million |
+12.28% |
| 2008-12-31 | Skr1.29 Billion ≈ $139.24 Million |
+161.12% |
| 2007-12-31 | Skr495.50 Million ≈ $53.32 Million |
-28.79% |
| 2006-12-31 | Skr695.87 Million ≈ $74.89 Million |
-31.81% |
| 2005-12-31 | Skr1.02 Billion ≈ $109.82 Million |
+196.35% |
| 2004-12-31 | Skr344.34 Million ≈ $37.06 Million |
+23.90% |
| 2003-12-31 | Skr277.92 Million ≈ $29.91 Million |
+4.25% |
| 2002-12-31 | Skr266.58 Million ≈ $28.69 Million |
-- |
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more